本研究的目的是评估诊断为急性髓系白血病 (AML) 的个体中 NAP1L5 的表达水平，并研究其在原发性 AML 患者中的临床和预后意义。 2021 年 6 月至 2023 年 6 月期间，血液科蚌埠医科大学第一附属医院为这项医学研究收集了100份原发性AML患者的骨髓标本和30份特发性血小板减少性紫癜（ITP）患者的骨髓标本。研究人员收集了诊断为急性髓系白血病（AML）患者的全面临床数据。利用实时定量聚合酶链反应（qRT-PCR）测量实验组和对照组中NAP1L5的mRNA水平。该调查涉及分析与 AML 相关的 NAP1L5 表达、临床特征和总体预后之间的关联。该研究采用Kaplan-Meier方法评估NAP1L5表达对AML患者总生存时间（OS）的影响，同时使用Cox风险回归模型来识别显着的预后因素。发现NAP1L5在AML患者中显着更高表达患有 AML 的个体与患有 ITP 的个体进行比较。被诊断为 AML 且 NAP1L5 表达水平升高的患者与年龄较大、对化疗反应无效以及与 NAP1L5 表达较低的患者相比预后更不利相关。此外，与低表达组相比，高表达组的总生存期（OS）显着降低。此外，在诊断为 AML 的患者中，观察到 NAP1L5 表达水平升高与不良临床结果之间存在显着关联。对 AML 中 NAP1L5 表达升高及其临床意义的初步探索为 AML 治疗和预后评估提供了潜在目标。

The objective of this study was to assess the expression levels of NAP1L5 in individuals diagnosed with acute myeloid leukemia (AML) and to investigate its clinical and prognostic significance in those with primary AML.Between June 2021 and June 2023, the Department of Hematology at the First Affiliated Hospital of Bengbu Medical University collected 100 bone marrow specimens from primary AML patients and 30 from individuals with idiopathic thrombocytopenic purpura (ITP) for this medical research study. The researchers gathered comprehensive clinical data from patients diagnosed with acute myeloid leukemia (AML). Quantitative real-time polymerase chain reaction (qRT-PCR) was utilized to measure the mRNA levels of NAP1L5 in both the ex-perimental and the control group. The investigation involved analyzing the association between NAP1L5 expres-sion related to AML, clinical features, and overall prognosis. The study employed the Kaplan-Meier method to evaluate the impact of NAP1L5 expression on the overall survival time (OS) in AML patients, while the Cox hazard regression model was used to identify significant prognostic factors.NAP1L5 was found to be significantly more expressed in individuals with AML compared to those with ITP. Patients diagnosed with AML and exhibiting elevated NAP1L5 expression levels correlated with older age, ineffective response to chemotherapy, and a more unfavorable prognosis compared to those with lower NAP1L5 expression. Additionally, the group with high expression demonstrated a noticeably decreased overall survival (OS), compared to the group with low expression. Furthermore, a significant association was observed between the elevated NAP1L5 expression levels and an unfavorable clinical outcome in patients diagnosed with AML.The initial exploration of the elevated expression of NAP1L5 in AML and its clinical significance offers potential targets for AML treatment and prognostic evaluation.